 |
|
inalimarev
A cancer vaccine comprised of a recombinant vaccinia viral vector encoding the carcinoembryonic antigen (CEA), MUC-1 (mucin-1), a transmembrane glycoprotein secreted by glandular tissues, and TRICOM, comprised of the three co-stimulatory molecule transgenes B7-1, ICAM-1 and LFA-3. Upon administration, inalimarev may enhance CEA and MUC-1 presentation to antigen presenting cells (APC) and may activate a cytotoxic T lymphocyte (CTL) response against CEA- and MUC-1-expressing tumor cells. Check for active clinical trials or closed clinical trials using this agent. (NCI Thesaurus)
| Synonyms: | | recombinant vaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
recombinant vaccinia-CEA-MUC1-TRICOM vaccine
rVaccinia-CEA(D609)/MUC1(L93)/TRICOM vaccine
vaccinia-CEA-MUC-1-TRICOM vaccine | | | | US brand name: | | PANVAC-V | | | | Abbreviation: | | vCEA-MUC-1-TRI | | |
|
|
